Sanctuary Wealth Advisors LLC acquired a new stake in shares of Puma Biotechnology Inc (NYSE:PBYI) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 35,788 shares of the biopharmaceutical company’s stock, valued at approximately $4,286,000. Puma Biotechnology comprises 3.3% of Sanctuary Wealth Advisors LLC’s portfolio, making the stock its 3rd largest holding. Sanctuary Wealth Advisors LLC owned approximately 0.10% of Puma Biotechnology as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Puma Biotechnology by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 2,474,644 shares of the biopharmaceutical company’s stock worth $216,284,000 after purchasing an additional 45,735 shares during the period. Janus Henderson Group PLC purchased a new position in shares of Puma Biotechnology in the 2nd quarter worth $162,302,000. BlackRock Inc. raised its position in shares of Puma Biotechnology by 5.0% in the 2nd quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock worth $159,973,000 after buying an additional 86,924 shares during the period. Franklin Resources Inc. purchased a new position in shares of Puma Biotechnology in the 2nd quarter worth $50,134,000. Finally, Emerald Advisers Inc. PA raised its position in shares of Puma Biotechnology by 16.5% in the 3rd quarter. Emerald Advisers Inc. PA now owns 370,035 shares of the biopharmaceutical company’s stock worth $44,312,000 after buying an additional 52,355 shares during the period. 80.98% of the stock is owned by hedge funds and other institutional investors.

In other news, SVP Richard Paul Bryce sold 15,000 shares of Puma Biotechnology stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the sale, the senior vice president now owns 42,239 shares of the company’s stock, valued at $5,068,680. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 22.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “35,788 Shares in Puma Biotechnology Inc (PBYI) Acquired by Sanctuary Wealth Advisors LLC” was reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/35788-shares-in-puma-biotechnology-inc-pbyi-acquired-by-sanctuary-wealth-advisors-llc/1700745.html.

Several research analysts recently weighed in on PBYI shares. Credit Suisse Group reaffirmed an “outperform” rating and issued a $118.00 target price (up from $90.00) on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Stifel Nicolaus reissued a “buy” rating and issued a $118.00 price objective (up from $105.00) on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Citigroup Inc. reissued a “buy” rating and issued a $114.00 price objective on shares of Puma Biotechnology in a research report on Tuesday, July 18th. J P Morgan Chase & Co restated a “buy” rating on shares of Puma Biotechnology in a research note on Tuesday, July 18th. Finally, Royal Bank Of Canada set a $88.00 target price on Puma Biotechnology and gave the company a “hold” rating in a research note on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Puma Biotechnology currently has a consensus rating of “Buy” and a consensus price target of $130.67.

Shares of Puma Biotechnology Inc (NYSE PBYI) traded down $24.20 during midday trading on Monday, reaching $103.00. 5,677,100 shares of the company’s stock were exchanged, compared to its average volume of 1,118,516. Puma Biotechnology Inc has a 1 year low of $28.35 and a 1 year high of $136.90.

Puma Biotechnology (NYSE:PBYI) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to the consensus estimate of $3.78 million. During the same period last year, the firm posted ($1.11) EPS.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.